Everett E. Vokes to Cyclin-Dependent Kinase Inhibitor p16
This is a "connection" page, showing publications Everett E. Vokes has written about Cyclin-Dependent Kinase Inhibitor p16.
Connection Strength
0.275
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.198
-
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol. 2008 Apr; 3(4):417-21.
Score: 0.077